Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure ...

These case studies demonstrate how integrated models are taking shape and what hospital leaders in children’s hospitals, can learn from them.

Health Secretary Robert F. Kennedy Jr.'s Centers for Disease Control and Prevention has launched an unprecedented review of ...

Learn more about new FDA recommendations on oral fluoride supplements and what doctors recommend for oral care in young ...

The FDA has updated the label indication for linaclotide capsules for the treatment of irritable bowel syndrome with ...

Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 ...

The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for ...

The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...